An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers

References

• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• van Nieuwenhuijzen N, Spaan I, Raymakers R, et al. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449–2456.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (Asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582–2590.
   Web of Science ®Google Scholar
• Ahn IE, Mailankody S, Korde N, et al. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol. 2015;33:115–123.
   Web of Science ®Google Scholar
• Mateos M-V, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematol Am Soc Hematol Educ Progr. 2017;2017:498–507. [ Internet]. [cited 2019 Feb 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29222298
   PubMedGoogle Scholar
• Avet-Loiseau H, Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018;32:1267–1276.
   Web of Science ®Google Scholar
• Bustoros M, Mouhieddine TH, Detappe A, et al. Established and novel prognostic biomarkers in multiple myeloma. Am Soc Clin Oncol Educ B. 2017;34:548–560.
   PubMedGoogle Scholar
• Greipp PR, Miguel JS, Dune BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
   Web of Science ®Google Scholar
• Harshman SW, Canella A, Ciarlariello PD, et al. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. J Proteomics. 2016;136:89–98.
   PubMed Web of Science ®Google Scholar
• Granell M, Calvo X, Garcia-Guiñón A, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102:1099–1104.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33:2863–2869.
   Web of Science ®Google Scholar
• Weinhold N, Heuck CJ, Rosenthal A, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30:423–430.
   Web of Science ®Google Scholar
• Chng WJ, Chung TH, Kumar S, et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016;30:1071–1078.
   Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015;125:2068–2074.
   Web of Science ®Google Scholar
• Castro-Giner F, Gkountela S, Donato C, et al. Cancer diagnosis using a liquid biopsy: challenges and expectations. Diagnostics. 2018;8:31.
   Web of Science ®Google Scholar
• Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750. [ Internet]. [cited 2019 Feb 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30637094
   PubMed Web of Science ®Google Scholar
• De Luca L, Trino S, Laurenzana I, et al. Mesenchymal stem cell derived extracellular vesicles: A role in hematopoietic transplantation?. Int J Mol Sci. 2017;18.
   Web of Science ®Google Scholar
• Caivano A, La Rocca F, Laurenzana I, et al. Extracellular vesicles in hematological malignancies: from biology to therapy. Int J Mol Sci. 2017;18.
   Web of Science ®Google Scholar
• Boyiadzis M, Whiteside TL. The emerging roles of tumor-derived exosomes in hematological malignancies. Leukemia. 2017;31:1259–1268.
   Web of Science ®Google Scholar
• De Luca L, Trino S, Laurenzana I, et al. MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: A new insight in transplantation. Oncotarget. 2016;7.
   Google Scholar
• De Luca L, D’Arena G, Simeon V, et al. Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58.
   Web of Science ®Google Scholar
• Circulating extracellular vesicles in human disease. N Engl J Med. 2018;379:2179–2181. [Internet]. [cited 2019 Feb 6]Available from: http://www.nejm.org/doi/10.1056/NEJMc1813170
   Google Scholar
• La Rocca F, Airoldi I, Di Carlo E, et al. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cell Oncol. 2017;40.
   Web of Science ®Google Scholar
• Caivano A, La Rocca F, Laurenzana I, et al. Epha3 acts as proangiogenic factor in multiple myeloma. Oncotarget. 2017;8.
   PubMedGoogle Scholar
• Raimondo S, Saieva L, Corrado C, et al. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal. 2015;13:8.
   PubMed Web of Science ®Google Scholar
• Arendt BK, Walters DK, Wu X, et al. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014;5.
   PubMedGoogle Scholar
• Tomofumi Yamamoto, Kosaka, N. Takahiro, O., et al. Understanding the role of extracellular vesicles in Lenalidomide-resistance multiple myeloma. Conference on 60th ASH Annual Meeting American Society Hematology 2018.
   Google Scholar
• Purushothaman A, Bandari SK, Liu J, et al. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J Biol Chem. 2016;291:1652–1663.
   PubMed Web of Science ®Google Scholar
• Gao F, Chiu SM, Motan DAL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7:e2062.
   Web of Science ®Google Scholar
• Xu S, De Veirman K, De Becker A, et al. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia. 2018;32:1500–1514.
   Google Scholar
• Laurenzana I, Lamorte D, Trino S, et al. Extracellular vesicles: a new prospective in crosstalk between microenvironment and stem cells in hematological malignancies. Stem Cells Int. 2018;2018:9863194.
   PubMed Web of Science ®Google Scholar
• Trino S, Lamorte D, Caivano A, et al. Micrornas as new biomarkers for diagnosis and prognosis, and as potential therapeutic targets in acute myeloid leukemia. Int J Mol Sci. 2018;19.
   Web of Science ®Google Scholar
• Wang J, Faict S, Maes K, et al. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget. 2016;7(25):38927–38945.
   Google Scholar
• Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123:1542–1555.
   PubMed Web of Science ®Google Scholar
• Wang J, Hendrix A, Hernot S, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555–566.
   Web of Science ®Google Scholar
• De Veirman K, Wang J, Xu S, et al. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Lett. 2016;377:17–24.
   PubMed Web of Science ®Google Scholar
• Solimando AG, Brandl A, Mattenheimer K, et al. JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia. 2018;32:736–743.
   PubMedGoogle Scholar
• Li HW, Xiao YY, Zhang X, et al. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBPβ. Blood. 2007;110(13):4373–4384.
   Web of Science ®Google Scholar
• Raffaghello L, Vacca A, Pistoia V, et al. Cancer associated fibroblasts in hematological malignancies. Oncotarget. 2015;6.
   Google Scholar
• Ciavarella S, Laurenzana A, De Summa S, et al. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer. 2017;17.
   PubMed Web of Science ®Google Scholar
• Frassanito MA, Desantis V, Di Marzo L, et al. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. J Pathol. 2018;247(2):241–253.
   Web of Science ®Google Scholar
• Plouffe SW, Hong AW, Guan K-L. Disease implications of the Hippo/YAP pathway. Trends Mol Med. 2015;21:212–222. [Internet]. [cited 2019 Feb 6]Available from: http://www.ncbi.nlm.nih.gov/pubmed/25702974
   PubMed Web of Science ®Google Scholar
• Ria R, Catacchio I, Berardi S, et al. HIF-1 of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res. 2014;20:847–858. [ Internet]. [cited 2019 Feb 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24297864
   PubMed Web of Science ®Google Scholar
• Wang J, De Veirman K, Faict S, et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 2016;239:162–173.
   Web of Science ®Google Scholar
• Di Noto G, Chiarini M, Paolini L, et al. Immunoglobulin free light chains and GAGs mediate multiple myeloma extracellular vesicles uptake and secondary NfΰB nuclear translocation. Front Immunol. 2014;5:517. [Internet]. [cited 2019 Feb 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25386176
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu XJ, Zeng C, et al. Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin. 2014;35.
   Web of Science ®Google Scholar
• Umezu T, Tadokoro H, Azuma K, et al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124:3748–3757.
   PubMed Web of Science ®Google Scholar
• Zarfati M, Avivi I, Brenner B, et al. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. Angiogenesis. 2018;22.
   PubMed Web of Science ®Google Scholar
• Leaf RK, Stroopinsky D, Pyzer AR, et al. DCOne as an allogeneic cell-based vaccine for multiple myeloma. J Immunother. 2017;40:315–322.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kosaka N, Hattori Y, et al. A challenge to aging society by microRNA in extracellular vesicles: microRNA in extracellular vesicles as promising biomarkers and novel therapeutic targets in multiple myeloma. J Clin Med. 2018;7:55.
   Web of Science ®Google Scholar
• Seo N, Akiyoshi K, Shiku H. Exosome-mediated regulation of tumor immunology. Cancer Sci. 2018;109:2998–3004.
   PubMed Web of Science ®Google Scholar
• Dörsam B, Reiners KS, von Strandmann EP. Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance. Philos Trans R Soc B Biol Sci. 2018;373:20160481.
   PubMedGoogle Scholar
• Umansky V, Blattner C, Fleming V, et al. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. 2017;39:295–305.
   PubMed Web of Science ®Google Scholar
• Morandi F, Marimpietri D, Horenstein AL, et al. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+. Oncoimmunology. 2018;e1458809.
   Web of Science ®Google Scholar
• Chillemi A, Quarona V, Antonioli L, et al. Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche. Front Immunol. 2017;8.
   PubMed Web of Science ®Google Scholar
• Malavasi F, Chillemi A, Castella B, et al. CD38 and antibody therapy: what can basic science add? Blood. 2016;128:SCI-36.
   PubMedGoogle Scholar
• Godfrey J, Benson DM. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012;53:1666–1676.
   PubMed Web of Science ®Google Scholar
• Garg TK, Gann JI, Malaviarachchi PA, et al. Myeloma-derived exosomes and soluble factors suppress natural killer cell function. In Proceedings of 58th ASH Annual Meeting and Exposition; 2016 December 3–6; San Diego, CA, USA. p. 2066.
   Google Scholar
• Vulpis E, Cecere F, Molfetta R, et al. Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: role of HSP70/TLR2/NF-kB axis. Oncoimmunology. 2017;6:e1279372.
   PubMed Web of Science ®Google Scholar
• Tran TH, Mattheolabakis G, Aldawsari H, et al. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin Immunol. 2015;160:46–58.
   PubMed Web of Science ®Google Scholar
• Yao Y, Chen L, Wei W, et al. Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+CTL responses and antitumor immunities. Biochem Biophys Res Commun. 2013;436:60–65.
   Web of Science ®Google Scholar
• Xie Y, Bai O, Zhang H, et al. Tumor necrosis factor gene-engineered J558 tumor cell–released exosomes stimulate tumor antigen P1A-specific CD8 + CTL responses and antitumor immunity. Cancer Biother Radiopharm. 2010;25:21–28.
   Web of Science ®Google Scholar
• Xie Y, Bai O, Zhang H, et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med. 2010;14:2655–2666.
   Web of Science ®Google Scholar
• Li Q, Huang Q, Huyan T, et al. Bifacial effects of engineering tumour cell-derived exosomes on human natural killer cells. Exp Cell Res. 2018;363(2):141–150.
   Web of Science ®Google Scholar
• Heusschen R, Muller J, Duray E, et al. Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leuk Lymphoma. 2018;59:14–28.
   PubMed Web of Science ®Google Scholar
• Costa F, Toscani D, Chillemi A, et al. Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget. 2017;8.
   Google Scholar
• Rossi M, Battafarano G, D’Agostini M, et al. The role of extracellular vesicles in bone metastasis. Int J Mol Sci. 2018;19:1136.
   Web of Science ®Google Scholar
• Raimondi L, De Luca A, Amodio N, et al. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget. 2015;6.
   Google Scholar
• Faict S, Muller J, De Veirman K, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8.
   PubMed Web of Science ®Google Scholar
• Zahoor M, Westhrin M, Aass KR, et al. Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Adv. 2017;1:2656–2666.
   PubMed Web of Science ®Google Scholar
• Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.
   PubMed Web of Science ®Google Scholar
• Di Marzo L, Desantis V, Solimando AG, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016;7.
   PubMedGoogle Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–548.
   PubMed Web of Science ®Google Scholar
• Caivano A, Laurenzana I, De Luca L, et al. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biol. 2015;36.
   PubMedGoogle Scholar
• Di Noto G, Bugatti A, Zendrini A, et al. Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes. Biosens Bioelectron. 2016;77:518–524. [Internet]. [cited 2019 Feb 6]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0956566315304577
   PubMed Web of Science ®Google Scholar
• Krishnan SR, Luk F, Brown RD, et al. Isolation of human CD138+microparticles from the plasma of patients with multiple myeloma. Neoplasia. 2016;18:25–32.
   PubMed Web of Science ®Google Scholar
• Arendt BK, Walters DK, Wu X, et al. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia. 2012;26:2286–2296.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014;28:373–383.
   Web of Science ®Google Scholar
• Ohwada C, Nakaseko C, Koizumi M, et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur J Haematol. 2008;80:245–250.
   PubMed Web of Science ®Google Scholar
• Yang X, Iyer AK, Singh A, et al. Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm Res. 2015;32:2097–2109.
   Web of Science ®Google Scholar
• Yoon C, Park DJ, Schmidt B, et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20:3974–3988.
   Web of Science ®Google Scholar
• Lia G, Brunello L, Bruno S, et al. Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. Leukemia. 2018;32:765–773.
   PubMed Web of Science ®Google Scholar
• Di Noto G, Paolini L, Zendrini A, et al. C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia. PLoS One. 2013;8:e70811.
   Web of Science ®Google Scholar
• Krzeminski P, Sarasquete ME, Misiewicz-Krzeminska I, et al. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochim Biophys Acta - Genet Regul Mech. 2015;1849:353–366.
   Web of Science ®Google Scholar
• Caivano A, La Rocca F, Simeon V, et al. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. Cell Oncol. 2017;40.
   Web of Science ®Google Scholar
• Rossi M, Di Martino MT, Morelli E, et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12:757–767.
   Web of Science ®Google Scholar
• Feng M, Luo X, Gu C, et al. Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. J Drug Target. 2015;23:59–66.
   Web of Science ®Google Scholar
• Manier S, Liu CJ, Avet-Loiseau H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129:2429–2436.
   PubMed Web of Science ®Google Scholar
• Jung SH, Lee SE, Lee M, et al. Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. Haematologica. 2017;102:e456-e459.
   PubMedGoogle Scholar
• Zhang L, Pan L, Xiang B, et al. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget. 2016;7.
   Google Scholar
• Nobili L, Ronchetti D, Agnelli L, et al. Long non-coding RNAs in multiple myeloma. Genes (Basel). 2018;9(2).
   PubMed Web of Science ®Google Scholar
• Cho SF, Chang YC, Chang CS, et al. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer. 2014;14.
   Web of Science ®Google Scholar
• Handa H, Kuroda Y, Kimura K, et al. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. Br J Haematol. 2017;179:449–460.
   PubMed Web of Science ®Google Scholar
• Sedlarikova L, Bollova B, Radova L, et al. Circulating exosomal long noncoding RNA PRINS—first findings in monoclonal gammopathies. Hematol Oncol. 2018;36:786–791.
   PubMed Web of Science ®Google Scholar
• Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma. Front Immunol. 2018;9.
   PubMed Web of Science ®Google Scholar
• Nishida-Aoki N, Tominaga N, Takeshita F, et al. Disruption of circulating extracellular vesicles as a novel therapeutic strategy against cancer metastasis. Mol Ther. 2017;25:181–191.
   PubMed Web of Science ®Google Scholar
• Kim S-M, Kim H-S. Engineering of extracellular vesicles as drug delivery vehicles. Stem Cell Investig. 2017;4:74.
   Google Scholar
• Paolini L, Zendrini A, Radeghieri A. Biophysical properties of extracellular vesicles in diagnostics. Biomark Med. 2018;12:383–391.
   PubMed Web of Science ®Google Scholar
• Van Deun J, Mestdagh P, Agostinis P, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228–232.
   PubMed Web of Science ®Google Scholar